Developing World Bioethics 12 (3):121-134 (2012)
Most of the world's health problems afflict poor countries and their poorest inhabitants. There are many reasons why so many people die of poverty-related causes. One reason is that the poor cannot access many of the existing drugs and technologies they need. Another, is that little of the research and development (R&D) done on new drugs and technologies benefits the poor. There are several proposals on the table that might incentivize pharmaceutical companies to extend access to essential drugs and technologies to the global poor.1 Still, the problem remains – the poor are suffering and dying from lack of access to essential medicines. So, it is worth considering a new alternative. This paper suggests rating pharmaceutical and biotechnology companies based on how some of their policies impact poor people's health. It argues that it might be possible to leverage a rating system to encourage companies to extend access to essential drugs and technologies to the poor
|Keywords||poverty developing countries developing world bioethics health pharmaceutical essential medicines neglected disease|
|Categories||categorize this paper)|
References found in this work BETA
No references found.
Citations of this work BETA
From Bad Pharma to Good Pharma: Aligning Market Forces with Good and Trustworthy Practices Through Accreditation, Certification, and Rating.Jennifer E. Miller - 2013 - Journal of Law, Medicine and Ethics 41 (3):601-610.
Global Justice and Charity: A Brief for a New Approach to Empirical Philosophy.Nicole Hassoun - 2014 - Philosophy Compass 9 (12):884-893.
Similar books and articles
Poverty, Disease, and Medicines in Low- and Middle-Income Countries.Klaus M. Leisinger - 2012 - Business and Professional Ethics Journal 31 (1):135-185.
Pharmaceutical Companies and Global Lack of Access to Medicines: Strengthening Accountability Under the Right to Health.Anand Grover, Brian Citro, Mihir Mankad & Fiona Lander - 2012 - Journal of Law, Medicine & Ethics 40 (2):234-250.
Common Health Policy Interests and the Shaping of Global Pharmaceutical Policies.Meri Koivusalo - 2010 - Ethics and International Affairs 24 (4):395-414.
Improving Access to Essential Medicines: How Health Concerns Can Be Prioritised in the Global Governance System.Devi Sridhar - 2008 - Public Health Ethics 1 (2):83-88.
Incentivizing Access and Innovation for Essential Medicines: A Survey of the Problem and Proposed Solutions.Michael Ravvin - 2008 - Public Health Ethics 1 (2):110-123.
Human Rights Responsibilities of Pharmaceutical Companies in Relation to Access to Medicines.Joo-Young Lee & Paul Hunt - 2012 - Journal of Law, Medicine & Ethics 40 (2):220-233.
Pharmaceutical Companies and Access to Medicines – Social Integration and Ethical CSR Resolution of a Global Public Choice Problem.Onyeka K. Osuji & Okechukwu Timothy Umahi - 2012 - Journal of Global Ethics 8 (2-3):139-167.
GlaxoSmithKline and Developing Country Access to Essential Medicines (A).N. Craig Smith & Anne Duncan - 2005 - Journal of Business Ethics Education 2 (1):97-121.
Why Restrictions on the Immigration of Health Workers Are Unjust.Javier Hidalgo - 2012 - Developing World Bioethics 12 (3):117-126.
Pharmaceutical Innovation and the Burden of Disease in Developing and Developed Countries.Frank R. Lichtenberg - 2005 - Journal of Medicine and Philosophy 30 (6):663 – 690.
Corporate Responsibilities for Access to Medicines.Klaus M. Leisinger - 2009 - Journal of Business Ethics 85 (1):3 - 23.
The Corporate Social Responsibility of The Pharmaceutical Industry.Klaus M. Leisinger - 2005 - Business Ethics Quarterly 15 (4):577-594.
In the High Court of South Africa, Case No. 4138/98: The Global Politics of Access to Low-Cost AIDS Drugs in Poor Countries. [REVIEW]David Barnard - 2002 - Kennedy Institute of Ethics Journal 12 (2):159-174.
Three Proposals for Rewarding Novel Health Technologies Benefiting People Living in Poverty. A Comparative Analysis of Prize Funds, Health Impact Funds and a Cost-Effectiveness/Competitive Tender Treaty.Thomas Alured Faunce & Hitoshi Nasu - 2008 - Public Health Ethics 1 (2):146-153.
Added to index2012-02-08
Total downloads19 ( #258,456 of 2,168,195 )
Recent downloads (6 months)1 ( #346,757 of 2,168,195 )
How can I increase my downloads?